Reviewing Sunwin Stevia International (SUWN) & Alimera Sciences (ALIM)

Sunwin Stevia International (OTCMKTS:SUWN) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Volatility and Risk

Sunwin Stevia International has a beta of 3.72, indicating that its share price is 272% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sunwin Stevia International and Alimera Sciences’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sunwin Stevia International $22.04 million 0.71 -$4.71 million N/A N/A
Alimera Sciences $46.97 million 1.77 -$16.38 million ($0.29) -4.03

Sunwin Stevia International has higher earnings, but lower revenue than Alimera Sciences.

Insider and Institutional Ownership

51.0% of Alimera Sciences shares are owned by institutional investors. 14.9% of Alimera Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sunwin Stevia International and Alimera Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sunwin Stevia International -16.60% -50.70% -12.53%
Alimera Sciences -34.87% N/A -97.94%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sunwin Stevia International and Alimera Sciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sunwin Stevia International 0 0 0 0 N/A
Alimera Sciences 0 0 3 0 3.00

Alimera Sciences has a consensus price target of $2.83, suggesting a potential upside of 142.17%. Given Alimera Sciences’ higher possible upside, analysts clearly believe Alimera Sciences is more favorable than Sunwin Stevia International.

Summary

Alimera Sciences beats Sunwin Stevia International on 7 of the 11 factors compared between the two stocks.

About Sunwin Stevia International

Sunwin Stevia International, Inc. produces and sells stevioside, a natural sweetener; and herbs used in traditional Chinese medicines and veterinary products primarily in the People's Republic of China. It operates through two segments, Stevioside and Chinese Medicines. The Stevioside segment produces and sells various steviol glycosides with rebaudioside A and stevioside as the principal components. Its products include Steviosin, a low calorie stevia extract for medicinal use; and OnlySweet, a zero calorie, dietary supplement. This segment sells its products to food and drug manufacturers, and ingredient distributor foreign trade companies. The Chinese Medicines segment manufactures and sells traditional Chinese medicine formula extracts, which are used in products made for use by humans and animals. Its extracts consists of single traditional Chinese medicine extracts; compound traditional Chinese medicine extracts; and purified extracts, including active parts and monomer compounds, such as soy isoflavone. This segment offers traditional Chinese medicine formula extracts to traditional Chinese medicine manufacturers and animal pharmaceutical manufacturers. Sunwin Stevia International, Inc. is based in Qufu, China.

About Alimera Sciences

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Receive News & Ratings for Sunwin Stevia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunwin Stevia International and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply